A clinical study of lupron depot in the treatment of women with Alzheimer's disease: Preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks

Journal of Alzheimer's Disease

Volumn 44, Issue 2, 2015, Pages 549-560

  Bowen, Richard L ^a   Perry, George ^b,c   Xiong, Chengjie ^d   Smith, Mark A ^c   Atwood, Craig S ^e,f,g  

^a OTB Research   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^g EDITH COWAN UNIVERSITY   (Australia)

Author keywords

17 estradiol; acetylcholinesterase inhibitor; Alzheimer's disease; apolipoprotein E; clinical trial; cognitive testing; gonadotropin releasing hormone; Lupron; luteinizing hormone; women

Indexed keywords

APOENZYME; CHOLINESTERASE INHIBITOR; ESTRADIOL; FOLLITROPIN; LEUPRORELIN; LUTEINIZING HORMONE; PLACEBO; DELAYED RELEASE FORMULATION; NOOTROPIC AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; BONE DENSITY; BRAIN HEMORRHAGE; COGNITION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEEP VEIN THROMBOSIS; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTRADIOL BLOOD LEVEL; FAINTNESS; FEMALE; FOLLITROPIN BLOOD LEVEL; GENOTYPE; HUMAN; LOW DRUG DOSE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MANTEL HAENSZEL TEST; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESPIRATORY FAILURE; UPPER GASTROINTESTINAL BLEEDING; BLOOD; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; PSYCHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LEUPROLIDE; LUTEINIZING HORMONE; NOOTROPIC AGENTS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84921505281     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141626     Document Type: Article

References (35)

1. Bowen RL, Atwood CS (2004) Living and dying for sex. A theory of aging based on the modulation of cell cycle signaling by reproductive hormones. Gerontology 50, 265-290.
2. Casadesus G, Webber KM, Atwood CS, Pappolla MA, Perry G, Bowen RL, Smith MA (2006) Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice. Biochim Biophys Acta 1762, 447-452.
3. Atwood CS, Meethal SV, Liu T, Wilson AC, Gallego M, Smith MA, Bowen RL (2005) Dysregulation of the hypothalamic-pituitary-gonadal axis with menopause and andropause promotes neurodegenerative senescence. J Neuropathol Exp Neurol 64, 93-103.
4. Atwood CS, Bowen RL (2011) The reproductive-cell cycle theory of aging: An update. Exp Gerontol 46, 100-107.
5. Bowen RL, Isley JP, Atkinson RL (2000) An association of elevated serum gonadotropin concentrations and Alzheimer disease? J Neuroendocrinol 12, 351-354.
6. Short RA, Bowen RL, O'Brien PC, Graff-Radford NR (2001) Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc 76, 906-909.
7. Bowen RL, Smith MA, Harris PL, Kubat Z, Martins RN, Castellani RJ, Perry G, Atwood CS (2002) Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. J Neurosci Res 70, 514-518.
8. Bowen RL, Verdile G, Liu T, Parlow AF, Perry G, Smith MA, Martins RN, Atwood CS (2004) Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition. J Biol Chem 279, 20539-20545.
9. Bowen RL, Beaird H, Atwood CS, Smith MA, Rimm AA. (2004) Men treated for prostate cancer have a decreased incidence of dementia. 9th International Conference on Alzheimer's Disease and Related Disorders, 17-22 July 2004, Philadelphia, Pennsylvania, USA.
10. D'Amico AV, Braccioforte MH, Moran BJ, Chen MH (2010) Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer disease. Alzheimer Dis Assoc Disord 24, 85-89.
11. Berry A, Tomidokoro Y, Ghiso J, Thornton J (2008) Human chorionic gonadotropin (a luteinizing hormone homologue) decreases spatial memory and increases brain amyloid-beta levels in female rats. Horm Behav 54, 143-152.
12. Casadesus G, Milliken EL, Webber KM, Bowen RL, Lei Z, Rao CV, Perry G, Keri RA, Smith MA (2007) Increases in luteinizing hormone are associated with declines in cognitive performance. Mol Cell Endocrinol 269, 107-111.
13. Bryan KJ, Mudd JC, Richardson SL, Chang J, Lee HG, Zhu X, Smith MA, Casadesus G Down-regulation of serum gonadotropins is as effective as estrogen replacement at improving menopause-associated cognitive deficits. J Neurochem 112, 870-881.
14. Lin J, Li X, Yuan F, Lin L, Cook CL, Rao Ch V, Lei Z (2010) Genetic ablation of luteinizing hormone receptor improves the amyloid pathology in a mouse model of Alzheimer disease. J Neuropathol Exp Neurol 69, 253-261.
15. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102.
16. Bowen RL, Verdile G, Liu T, Parlow AF, Perry G, Smith MA, Martins RN, Atwood CS (2004) Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition. J Biol Chem 279, 20539-20545.
17. Chrisp P, Sorkin EM(1991) Leuprorelin.Areviewof its pharmacology and therapeutic use in prostatic disorders. Drugs Aging 1, 487-509.
18. Periti P, Mazzei T, Mini E (2002) Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet 41, 485-504.
19. Ziaran S, Goncalves FM, Sn JB (2013) Complex metabolic and skeletal changes in men taking long-term androgen deprivation therapy. Clin Genitourin Cancer 11, 33-38.
20. Yu EY, Kuo KF, Gulati R, Chen S, Gambol TE, Hall SP, Jiang PY, Pitzel P, Higano CS (2012) Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer. J Clin Oncol 30, 1864-1870.
21. Spry NA, Galvao DA, Davies R, La Bianca S, Joseph D, Davidson A, Prince R (2009) Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: Results of a 33-month observational study. BJU Int 104, 806-812.
22. Khosla S, Melton LJ, 3rd, Riggs BL (2001) Estrogens and bone health in men. Calcif Tissue Int 69, 189-192.
23. Palomba S, Morelli M, Di Carlo C, Noia R, Pellicano M, Zullo F (2002) Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone. Feril Infertil 78, 63-68.
24. Mitwally MF, Gotlieb L, Casper RF (2002) Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause 9, 236-241.
25. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P (2012) Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 366, 893-903.
26. D'Amico AV, Braccioforte MH, Moran BJ, Chen MH Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer disease. Alzheimer Dis Assoc Disord 24, 85-89.
27. Herman AP, Krawczynska A, Bochenek J, Haziak K, Romanowicz K, Misztal T, Antushevich H, Herman A, Tomaszewska-Zaremba D (2013) The effect of rivastigmine on the LPS-induced suppression of GnRH/LH secretion during the follicular phase of the estrous cycle in ewes. Anim Reprod Sci 138, 203-212.
28. Kaur G (2001) Role of cholinergic and GABAergic neurotransmission in the opioids-mediated GnRH release mechanism of EBP-primed OVX rats. Mol Cell Biochem 219, 13-19.
29. Lu F,Yang JM,Wu JN, Chen YC, Kao YH, Tung CS,Yang SN (1999) Activation of gonadotropin-releasing hormone receptors produces neuronal excitation in the rat hippocampus. Chin J Physiol 42, 67-71.
30. Yang SN, Lu F, Wu JN, Liu DD, Hsieh WY (1999) Activation of gonadotropin-releasing hormone receptors induces a long-term enhancement of excitatory postsynaptic currents mediated by ionotropic glutamate receptors in the rat hippocampus. Neurosci Lett 260, 33-36.
31. Wilson AC, Salamat MS, Haasl RJ, Roche KM, Karande A, Meethal SV, Terasawa E, Bowen RL, Atwood CS (2006) Human neurons express type I GnRH receptor and respond to GnRH I by increasing luteinizing hormone expression. J Endocrinol 191, 651-663.
32. Meethal SV, Liu T, Chan HW, Ginsburg E, Wilson AC, Gray DN, Bowen RL, Vonderhaar BK, Atwood CS (2009) Identification of a regulatory loop for the synthesis of neurosteroids: A steroidogenic acute regulatory protein-dependent mechanism involving hypothalamic-pituitary-gonadal axis receptors. J Neurochem 110, 1014-1027.
33. Bowen RL, Smith MA, Harris PL, Kubat Z, Martins RN, Castellani RJ, Perry G, Atwood CS (2002) Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. J Neurosci Res 70, 514-518.
34. Bryan KJ, Mudd JC, Richardson SL, Chang J, Lee HG, Zhu X, Smith MA, Casadesus G (2010) Down-regulation of serum gonadotropins is as effective as estrogen replacement at improving menopause-associated cognitive deficits. J Neurochem 112, 870-881.
35. Rosario ER, Carroll JC, Pike CJ (2012) Evaluation of the effects of testosterone and luteinizing hormone on regulation of beta-amyloid in male 3xTg-AD mice. Brain Res 1466, 137-145.